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Abstract
Human prion diseases are a group of transmissible, progressive, and invariably fatal neurodegenerative disorders,
which include Kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome, and fatal familial
insomnia. Human prion diseases affect approximately 1–2 persons per million worldwide annually, occurring in
sporadic, inherited, and acquired forms. These diseases have attracted both scientific and public attention not only
because of their mysterious pathogen, but also due to their considerable threat to public health since the emergence
of the variant CJD.
There are still no specific therapeutic and prophylactic interventions available for prion diseases, thus active surveillance
of human prion diseases is critical for disease control and prevention. Since 1993, CJD surveillance systems have been
established in many countries and regions, and several long-term multinational cooperative projects have been
conducted.
In this paper, the epidemiological characteristics of various human prion diseases and the active surveillance systems
pertaining to them in different countries and regions are summarized and reviewed.
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Background
Human prion diseases, also named transmissible spongi-
form encephalopathies (TSEs), are fatal neurodegenerative
disorders, which include Kuru, Creutzfeldt-Jakob disease
(CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS),
and fatal familial insomnia (FFI). These various subtypes
have different characteristics based on the onset times/dura-
tions of the disease, genetic/family histories of the patients,
clinical manifestations, neuropathology, and scrapie-like
prion protein (PrPSc) molecular features [1, 2]. It is widely
accepted that TSEs result from the conformational con-
version of a normal cellular prion protein (PrPC) into an
abnormal misfolded pathological form (PrPSc). An accu-
mulation of PrPSc leads to the onset of TSEs, which
attack the central nervous system, resulting in progressive
neuronal degeneration and neuronal vacuolation [3].
Currently, Kuru is virtually extinct due to a ban on
ritualistic cannibalism in the area of Papua New Guinea
where it was endemic. Most of the human prion diseases
are CJD, which consist of three main catalogues: spor-
adic, genetic, and acquired [1]. Approximately 85–90 %
of CJD cases occur sporadically and affect 1–1.5 people
per million annually [4]. Familial/genetic CJD (fCJD/
gCJD) account for about 10 % of CJD cases worldwide
[5]. Acquired prion diseases include variant CJD (vCJD)
and iatrogenic CJD (iCJD), and are observed in 2–5 % of
CJD cases. Depending on the origin of the causative
agent, human prion diseases can be divided into two
groups: caused by prions originating internally, such as
in the case of fCJD/gCJD, GSS, and FFI; or infected by
external prions, such as in the case of Kuru, iCJD, and
vCJD [6].
The pathogenesis of sporadic CJD (sCJD) is little
known. Many case–control studies on the risk factors
for sCJD have been conducted, with varying results, but
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no consistent data are available [7–12]. However, the
opportunity of external prion infection is still not easy to
be excluded definitely during long life-span [13].
As there are no specific therapeutic and prophylactic in-
terventions available for prion diseases, active surveillance
is critical for the control and prevention of human prion
diseases, especially those diseases caused by animal-derived
prion agents. Since 1993, many national CJD surveillance
systems have been established and several multinational
cooperative organizations have also been set up for CJD
surveillance and research [14–18]. In the present review,
the epidemiological characteristics of various subtypes of
human prion diseases and the active surveillance systems
pertaining to them are summarized and discussed.
Epidemiological characteristics of human prion
diseases
sCJD
CJD was first described in the early 1920s [19, 20]. The
predominant subtype of human prion diseases, sCJD,
occurs equally in both sexes with a peak age of onset
between 60 and 69 years [21–23]. sCJD occurs all year
round, with no seasonal specificity. Typical clinical
symptoms include progressive dementia, accompanied
by visual and cerebellum function abnormalities, myoclo-
nia, pyramidal and extrapyramidal dysfunction, or akinetic
mutism [2, 21]. The duration of sCJD cases is relatively
short. The median survival time of Chinese sCJD cases is
7.1 months (range: 1.0–23.3) and 78.5 % of patients die
within one year of onset [24]. These data are comparable
with that of Western countries but differ to data from
Japan. A study conducted by the European CJD Surveil-
lance Network (EuroCJD) involving 2,451 sCJD patients,
who died between 31 December 1992 and 31 December
2002, revealed that the median survival time was five
months (range: 1–81) and that 85.8 % of patients died
within one year of onset [25]. In Argentina, the median
disease duration of sCJD (calculated using 150 definite
and probable cases from available data) is 4.6 months
(range: 1–70) [17]. On the contrary, a survey by the Japa-
nese CJD surveillance program showed significantly lon-
ger disease durations in Japanese patients with prion
diseases (most of them with the sCJD subtype), in which
the mean disease duration of 855 patients was 17.4 months
and only 46.0 % died within one year of onset. This is
likely attributed to the country’s healthcare system, which
provides intensive life-sustaining treatment for patients
[26]. There is no accessible data for sCJD cases in South
Asia or Africa.
An international study on the epidemiologic character-
istics of sCJD involving 3,720 sCJD cases from nine
European countries, as well as from Australia and
Canada, revealed that the overall annual mortality rate
from sCJD is 1.39 per million [27]. In Japan, the age-
adjusted mortality rates have increased from 1979 to
2004, with the annual mortality rate of 1.48 per million
in 2004 [28]. The Chinese CJD surveillance network
reported that the annual CJD morbidity rate in Beijing is
0.91 per million [29]. The recognition of CJD clinically
and the undertaking of national CJD surveillance influ-
ences a country’s mortality rate. According to the latest
data from the CJD International Surveillance Network
(formerly the EuroCJD), the countries with the highest
mean mortality rates per million from sCJD are France
and Switzerland (1.51 and 1.72, respectively). The mean
mortality rates per million from sCJD from 1993 to 2013
of some countries are shown in Fig. 1a; 16 out of 28
countries have a mean mortality rate per million greater
than 1.0. Averaging the annual data from all countries in
the CJD International Surveillance Network from 1993 to
2013 results in the mortality rates per million increased
(see Fig. 1b). In the United States (US), the annual mortal-
ity rate is approximately one per million based on data
from 1979 to 2006 [30]. However, it is important to note
that most CJD cases from these data were European
Americans (94.6 %) and that the age-adjusted incidence of
whites is 2.7 times higher than that of African Americans
(1.04 and 0.40, respectively) [30], and is also higher than
that of Native Americans and Alaska Natives (0.47) [31].
Although reasons for such disparities are unclear, it is
possible that genetic differences and/or under diagnosis
among non-white patients are two associated factors.
Genetic human prion diseases
The human gene encoding for the prion protein (PrP),
PRNP, is located on chromosome 20p12 in humans. To
date, more than 40 mutations in the PRNP gene have been
directly linked to familial prion diseases, including fCJD/
gCJD, GSS, and FFI [32]. These mutations include point
mutations in the PRNP sequence, and octapeptide repeat
insertions or deletions in PrP’s N-terminus. Several epi-
demiological surveys report that some patients with gen-
etic prion diseases lack definite family history [33, 34].
The distribution and frequency of mutations in the
PRNP gene vary significantly among geographical areas
and human races. In gCJD/fCJD, the three most com-
mon PRNP mutations in European Caucasians, North
Americans, and Australians are E200K, V210I, and D178N/
129 V [34]. Interestingly, E200K is the only mutation in the
PRNP gene reported in the Slovak population, whereas only
one E200K gCJD case was identified in the population of
Switzerland between 1996 and 2002, and no E200K gCJD
has been reported after this. The proportionate incidence
of the V210I mutation in the Italian population is obvi-
ously higher than that in other ten countries (50 out of
69 V210I gCJD cases are observed in Italy), according to
data from the EuroCJD 1993–2002 [35]. In Japan, the
most frequently observed mutation in the PRNP gene is
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V180I, followed by E200K and M232R [16], while the
mutations T188K and E200K are most frequent in China
[36]. Five mutations in codon 180, three in codon 200,
two in codon 203, and two in codon 232 have been iden-
tified in the Republic of Korea [37–42]. The frequency of
gCJD cases in the Republic of Korea is similar to that in
Japan, but differs from that in China (see Table 1) [43]. In
addition, the V210I mutation is prevalent in European
countries but is rare in East Asian populations. M232R,
which is one of the most frequently described gCJD-
associated mutations in the Japanese, is rarely identified
among Europeans.
The distribution and frequency of mutations in the
PRNP gene causing GSS are also clearly distinct between
Caucasians and East Asians. Although the most com-
mon mutation causing GSS in Caucasian and East Asian
patients is P102L, the mutation P105L is only observed
in East Asian populations, especially in the Japanese,
while the mutation A117V is exclusively reported in
Caucasians.
Fig. 1 The mean mortality rates per million from sCJD according to the data of the CJD International Surveillance Network from 1993 to 2013. a Data
from the member states of the CJD International Surveillance Network. The mortality rate of one per million is marked with a dotted line. b The mean
mortality rates per million of all member states. Solid line represents the fitting trend
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FFIs caused by the mutation D178N in the PRNP gene
associated with the M129 genotype have been reported
worldwide. However, there are also clear geographical
and race-associated variations. FFI is predominant in
some regions of Europe, such as in Spain and Germany,
where 56.8 % (25/44) and 25 % (17/68) of genetic prion
diseases are FFI, respectively [34]. It is worth emphasiz-
ing that FFI cases are common in the Han Chinese
population, which reaches to the first most common
PRNP mutation in all identified mutations associated
with genetic prion diseases in China [36], revealing a
distinct profile compared with those in Japan and Korea
(see Table 1). A study further addressing PRNP muta-
tions among different ethnic groups is warranted.
The age at onset of genetic prion diseases is often earl-
ier than that of sCJD, ranging from 30 to 55 years for
gCJD, 40 to 60 years for GSS, and 20 to 72 years for FFI
[43]. Although gCJD cases with point mutations have an
earlier median age of death compared with that of sCJD
cases, there is no difference between gCJD cases with
point mutations and sCJD in the mean duration of the
disease [44–46]. Meanwhile, gCJD cases with extra in-
sertional octarepeat sequences, as well as GSS and FFI
cases often have a relatively protracted duration of ill-
ness in Caucasians [34, 47, 48]. Relatively long clinical
durations are also observed in Chinese FFI cases [49]
and Japanese GSS patients [26].
In addition to these disease-related mutations, poly-
morphisms have also been described in PrP [32, 50]. In
particular, single nucleotide polymorphisms (SNPs) at
codons 129 and 219 of the PRNP gene represent sus-
ceptibility factors for human prion diseases [51, 52].
The pattern of SNP at codon 129 greatly varies between
Caucasians and East Asians. An overwhelming percent-
age of East Asians (92 % to 94 %) exhibit methionine/
methionine homozygote at codon 129 (M129M), but a
much lower percentage of Caucasians have this poly-
morphism (32 % to 45 %) [43]. Homozygosity at
codon129 (M/V polymorphism) is a strong risk factor
for the development of sCJD in Caucasians [15, 53–55].
Moreover, all vCJD cases with clinical symptoms and
genetic analysis worldwide are M129M homozygous
[56]. Homozygosity at a different PRNP polymorphism,
E219K, seems to also be a risk factor for the develop-
ment of sCJD in Korean and Japanese populations, but
not in Caucasian populations [16, 52, 57–59]. In
addition, PRNP codon 129 polymorphism has obvious
effects on the clinical, neuropathological, and patho-
genic features of prion disease. For instance, in the
population with the D178N mutation in the PRNP
gene, the codon 129 polymorphism determines the type
of disease: people with the M129M mutation suffer
from FFI and those with the M129V mutation acquire
gCJD [60, 61].
Table 1 The distribution of genetic prion diseases in European and East Asians countries
Diseases Mutations Europeans [27] East Asians [10, 29, 31–35] P-valuea
Total (n = 420) China (n = 62) Japan (n = 216) Korea (n = 15) Total (n = 293)
gCJD Insertion 39 2 3 0 5 P < 0.001
N171S-129 V 1 0 0 0 0 n.s.
D178N-129 V 16 0 1 0 1 P < 0.01
V180I-129 M 1 1 89 5 95 P < 0.001
T188A-129 M 3 0 0 0 0 n.s.
T188K-129 M 0 16 0 0 16 P < 0.001
E196K-129 M/V 5 1 0 0 1 n.s.
E200K-129 M/V 175 9 37 3 49 P < 0.001
V203I-129 M 5 1 2 2 5 n.s.
R208H-129 M 2 2 1 0 3 n.s.
V210I-129 M 69 0 0 0 0 P < 0.001
E211Q-129 M 4 0 0 0 0 n.s.
M232R-129 M 0 0 33 2 35 P < 0.001
GSS P102L-129 M 24 3 39 2 44 P < 0.001
P105L-129 M 0 0 5 0 5 P < 0.05
A117V-129 V 12 0 0 0 0 P < 0.01
FFI D178N-129 M 64 27 3 1 31 n.s.
aThe differences of frequencies of PRNP mutations between Europeans and East Asians were measured by the Chi-square test or Fisher’s exact test. gCJD, genetic
Creutzfeldz-Jakob diseases; GSS, Gerstmann-Sträussler-Scheinker syndrome; FFI, fatal familial insomnia; n.s., not significant
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iCJD
In 1974, iatrogenic CJD (iCJD) was firstly described in a
person who received cadaveric corneal transplant from a
patient with CJD [62]. Since then, several cases of hu-
man prion disease have been confirmed to be associated
with iatrogenic transmission of CJD by the use of stereotac-
tic intracerebral electroencephalogram needles or neurosur-
gical instruments [63–67]. Additionally, corneal grafts and
the gonadotropin hormone [68, 69] can also cause iCJD.
Because of the long incubation time of iCJD, it is usually
very difficult to attribute the disease to a special medical
service in the lifespan of a patient. Therefore, the numbers
of iCJD cases might be underestimated. Historically, large
outbreaks of human iCJD cases have been reported via two
different medical pathways: one is cadavericdura mater
grafts [16], and the other is intramuscular injection of
contaminated cadaveric pituitary-derived human growth
hormone (hGH) and gonadotropin hormone [70]. Since the
first identification of dura mater graft-associated iCJD in
1987, at least 228 cases have been reported worldwide.
Nearly two thirds of cases come from Japan, with some
European countries, such as France, Spain, Germany, Italy,
and the Netherlands, also reporting iCJD. Cases have also
been reported from Australia (five cases), South Africa (one
case), Argentina (one case), the US (four cases), and South
Korea (two cases) [68]. At least 226 hGH-related iCJD case-
shave been reported worldwide, mostly in France (119
cases), the United Kingdom, UK (65 cases) and the US
(29 cases), and a few cases in Brazil (two cases), New
Zealand (six cases) and Qatar (one case) [68]. The global
distribution of iCJD cases associated with dura mater
grafts and the hGH is shown in Fig. 2. With the availabil-
ity of recombinant hGH and the initiation of separated
processing of individual dura mater grafts, the transmis-
sion pathways of these two kinds of iCJD have been suc-
cessfully eradicated and almost no new cases have been
reported in the past few years [70]. So far, there have been
no reports of dura mater graft-associated or hGH-related
iCJD in China.
The clinicopathological features of dura mater graft-
associated iCJD cases resemble those of sCJD cases. How-
ever, in Japan, approximately one third of these cases have
atypical features (slow progression, non-characteristic
electroencephalogram tracings, plaque deposition, and an
atypical prion protein molecular signature on Western
blots), suggesting the possibility of two different types of
infectious agents [71, 72]. The incubation periods are in
the range of 1.3 to 30 years (mean: 12) worldwide [68].
The clinicopathological features of hGH-related iCJD
cases resemble those of Kuru. The incubation periods
vary from five to 42 years worldwide (mean:17) [68].
Those with the M129M mutation are at risk for acquiring
hGH-related iCJD in France and in the US, but not in the
UK [68, 73, 74].
vCJD
The first 10 vCJD cases were reported in April 1996 in the
UK [70, 75]. As of April 2015, 229 vCJD cases have been
reported from seven European (UK, France, Spain, Republic
of Ireland, Netherlands, Italy, and Portugal) and five non-
European countries or regions (US, Canada, Saudi Arabia,
Japan, and China-Taiwan). Among them, 177 cases were
reported from the UK [76]. In 2000, the annual number of
deaths from vCJD in the UK reached a peak of 28. Since
2006, the annual deaths from vCJD have dramatically
reduced, with 2–5 from 2006 to 2011, none in 2012, and
only one in 2013 [77]. Since 2014, no more vCJD cases
have been reported (see Fig. 3). Outside of the UK, France
is the most affected country, with 27 vCJD cases reported
from 1996 to 2014, which is thought to be related to the
peak in the volume of beef imports from the UK from 1985
to 1995 [78]. This potential relationship is shown by the
peak of the number of deaths from vCJD in France in 2005,
five years after a similar peak in the number of deaths
occurred in the UK [78, 79]. Additionally, three East Asian
vCJD cases has been identified in Hong Kong SAR [80],
Japan [81, 82], and China-Taiwan [83]. All three are
assumed to be imported cases from the UK due to patients
who either previously resided in or travelled to the UK
bringing them in. The median age of onset is 27 years
(range: 12–74) and the median duration of the disease is
14 months in the UK (range: 6–40). In France, despite a
median age of onset is 35 years (range: 18–57), which is
higher than in the UK, all other data are similar [84]. The
disease duration in Asians (mean 28.3, range 14–43
months) seems to be longer than in patients in the UK
and France [83]. A further study supports the hypothesis
that a single strain of infectious agent is responsible for
all vCJD infections [85]. Probable secondary transmission
of vCJD via blood transfusions has been reported [86].
Animal experiments have shown that the M129V hetero-
zygote is less sensitive to the transmission of vCJD and
bovine spongiform encephalopathy (BSE) agents [87, 88].
Thus, vCJD with long incubation periods in individuals
with M129V and V129Vgenotypes and secondary iatro-
genic transmission of vCJD are still serious public health
concerns [89–93].
Surveillance of human prion diseases
Due to the impact that the BSE outbreak and the emer-
gence of vCJD has had on public health, many countries
and regions have initiated or re-initiated their surveillance
programs for human prion diseases. Initially, two major
surveillance networks for human prion diseases were cre-
ated by the European Commission. One is the EuroCJD
established in 1993 by seven countries (Austria, France,
Germany, Italy, Netherlands, Slovakia, and the UK), which
was later expanded to other European and non-European
countries such as Australia, Canada, and Spain. The other
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one is NeuroCJD initiated in 1998, which includes all the
other European countries and Israel [18, 34, 79]. In 2008,
the CJD International Surveillance Network (formerly
EuroCJD) was launched and funded by the European
Center for Disease Prevention and Control (CDC)
[94, 95]. The network includes 28 collaborating centers
from European Union (EU) Member States, European Free
Trade Association countries, and eight non-EU countries/
regions (Argentina, Australia, Japan, Canada, Mexico, China,
Israel, USA, and China-Taiwan) (see Fig. 4). The primary
objective of the network is to identify all cases of vCJD in
the EU and provide accurate data on the worldwide inci-
dence of vCJD through collaborations with other non-EU
countries.
Besides these major CJD surveillance networks, there
are several other CJD surveillance and/or research groups
intra- and internationally, including CJD surveillance in
Central and Eastern European countries [96]. NeuroPrion,
which aims to structure and integrate the efforts of the
main European prion research teams for the effective
management of prion diseases is funded by the European
Commission and has been operating since 2003 [18]. In
1997, the National Prion Disease Pathology Surveillance
Center of the US was established at the Case Western Re-
serve University [97] and the following year, the Canadian
CJD surveillance system was initiated by the Public Health
Agency of Canada [98]. In 1999, the CJD Surveillance
Committee was established at the Kanazawa University of
Japan, which started carrying out surveillance of CJD
nationwide [16]. The CJD surveillance program in the
Republic of Korea was established in 2001 and it is sup-
ported by the Korean CDCs [18]. In 2006, the China CJD
surveillance program was initiated, which is supported by
the Chinese CDC [22].
Fig. 3 Number of deaths from vCJD in the UK and outside of the UK from 1995 to 2015
Fig. 2 The distribution ofdura mater graft-associated and hGH-related iCJD casesglobally
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CJD surveillance systems have some unique features
compared with other public health surveillance systems.
One is that due to a lack of approved biomarkers for CJDs,
specific types of clinical and laboratory approaches are crit-
ical to effectively diagnose and monitor CJDs. The other is
that CJD surveillance systems are primarily dependent on
reports from physicians, especially neurologists and neuro-
pathologists in regional hospitals and medical centers
where first visit for most patients. Thus, the experiences of
these specialists directly determine the quality of the col-
lected specimens, such as accurate identify the clinical
manifestations of CJD or supply the appropriate specimens
to CJD surveillance center. Both aspects seriously impact
the sensitivity of CJD surveillance.
Conclusion
Human prion diseases are invariably fatal neurodegener-
ative disorders. The emergence of the novel prion strain,
which include the causative agent of vCJD, has created
an important public health concern. New prion strains
continually emerge in livestock, and their threats to
other domestic animals and humans are uncertain and
need long-term evaluation and assessment. Strategies for
early diagnosis of and therapies to treat human prion
diseases remain unavailable. Therefore, except for devel-
oping treatment for prion diseases, the most feasible
method to prevent these diseases from spreading, either
via human-to-human or zoonotic transmission, is active
surveillance and improving the sensitivity and specificity
of laboratory diagnostic procedures. This will require
more clinicians and experts participating in regional, na-
tional, and global systems by investing more of an effort
toward reliable and accurate diagnostic methods for the
control of prion diseases.
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